10:28 AM EST - BELLUS Health Inc. : Announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily Immediate Release formulation. Camlipixant is the Company’s twice-daily, oral P2X3 antagonist product candidate for the treatment of RCC currently being investigated in the CALM Phase 3 program. BELLUS Health Inc.
shares T.BLU are trading down $0.29 at $9.04.
